WHO ICTRP trial
The trial is designed to determine the efficacy of OGX-427 Vs placebo in…
EUCTR2011-002424-41-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-002424-41-DE |
|---|---|
| Public title | The trial is designed to determine the efficacy of OGX-427 Vs placebo in combination with Gemcitabine and Cisplatin in patients with Urinary tract cancer. |
| Scientific title | A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma |
| Primary sponsor | OncoGenex Technologies, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | France;United States;Canada;Poland;Spain;Germany;Italy |
| Conditions | Metastatic or locally inoperable, advanced (T4b, N2, N3 or M1) transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis) MedDRA version: 17.0 Level: PT Classification code 10005084 Term: Bladder… |
| Interventions | Product Code: OGX-427 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not applicable CAS Number: 915443-09-3 Current Sponsor code: OGX-427 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal… |
| Registration date | Aug 24, 2011 |
| Target size | 180 |
| Secondary IDs | OGX-427-02 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: